LabTest 29dec2023

Patient Name : Ms.
PRIYANKA KUMARI Collected : 28/Dec/2023 08:18AM

Age/Gender : 25 Y 9 M 14 D /F Received : 28/Dec/2023 11:07AM
UHID/MR No : APJ1.0017898558 Reported : 28/Dec/2023 12:21PM
Visit ID : DPATOPV50293 Status : Final Report
Ref Doctor : Dr.SELF Client Name : APOLLO 24X7
IP/OP NO : Patient location : khajpura,Patna
DEPARTMENT OF HAEMATOLOGY
Test Name Result Unit Bio. Ref. Range Method
HAEMOGLOBIN , WHOLE BLOOD EDTA 14.3 g/dL 12-15 Spectrophotometer
Page 1 of 15
SIN No:HA06254774
This test has been performed at Apollo Health and Lifestyle Ltd/Reference Regional Lab, Patna
Patient Name : Ms.PRIYANKA KUMARI Collected : 28/Dec/2023 12:37PM
Age/Gender : 25 Y 9 M 14 D /F Received : 28/Dec/2023 01:23PM
DEPARTMENT OF BIOCHEMISTRY
GLUCOSE, POST PRANDIAL (PP), 2 93 mg/dL 70-140 GOD - POD

HOURS , SODIUM FLUORIDE PLASMA (2
HR)
Comment:
It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each
other.
Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive
hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin
preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.
Page 2 of 15
SIN No:BI17587463
Patient Name : Ms.PRIYANKA KUMARI Collected : 28/Dec/2023 08:18AM
APOLLO PCOD COMPREHENSIVE
LIPID PROFILE , SERUM

TOTAL CHOLESTEROL 132 mg/dL <200 CHE/CHO/POD
TRIGLYCERIDES 122 mg/dL <150 Enzymatic
HDL CHOLESTEROL 34 mg/dL >40 CHE/CHO/POD
NON-HDL CHOLESTEROL 98 mg/dL <130 Calculated
LDL CHOLESTEROL 73.6 mg/dL <100 Calculated
VLDL CHOLESTEROL 24.4 mg/dL <30 Calculated
CHOL / HDL RATIO 3.88 0-4.97 Calculated
Comment:
Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.
Desirable Borderline High High Very High
TOTAL CHOLESTEROL < 200 200 - 239 ≥ 240
TRIGLYCERIDES <150 150 - 199 200 - 499 ≥ 500
Optimal < 100
LDL 130 - 159 160 - 189 ≥ 190
Near Optimal 100-129
HDL ≥ 60
Optimal <130;
NON-HDL CHOLESTEROL 160-189 190-219 >220
Above Optimal 130-159
1. Measurements in the same patient on different days can show physiological and analytical variations.
2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process
by which cholesterol is eliminated from peripheral tissues.
5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a
family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl.
When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.
Page 3 of 15
SIN No:BI17587461
URIC ACID , SERUM 4.78 mg/dL 2.5-6.2 Uricase
Page 4 of 15
SIN No:BI17587461
UHID/MR No : APJ1.0017898558 Reported : 29/Dec/2023 11:52AM
HOMA IR (INSULIN RESISTANCE INDEX)

INSULIN (FASTING) 9.56 µIU/mL 1.9-23 CLIA
FASTING GLUCOSE 79 mg/dL 70-100 GOD - POD
BETA CELL FUNCTION (%B) 143.1 % CALCULATED
INSULIN SENSITIVITY (%S) 83.7 % CALCULATED
HOMA INDEX 1.19 <3 CALCULATED
Comment:
HOMA INDEX INTERPRETATION
<3 Normal Insulin Resistance

Between 3 and 5 Moderate Insulin Resistance
>5 Severe Insulin Resistance
Page 5 of 15
SIN No:BI17587462
This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory,Hyderabad
DEPARTMENT OF IMMUNOLOGY
THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM

TRI-IODOTHYRONINE (T3, TOTAL) 1.44 ng/mL 0.7-2.04 CLIA
THYROXINE (T4, TOTAL) 14.79 µg/dL 5.48-14.28 CLIA
THYROID STIMULATING HORMONE 3.355 µIU/mL 0.34-5.60 CLIA
(TSH)
Comment:
Bio Ref Range for TSH in uIU/ml (As per American
For pregnant females
Thyroid Association)
First trimester 0.1 - 2.5
Second trimester 0.2 – 3.0
Third trimester 0.3 – 3.0
1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine).
Increased blood level of T3 and T4 inhibit production of TSH.
2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often
referred to as sub-clinical hypo- or hyperthyroidism respectively.
3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small
fraction of circulating hormone is free and biologically active.
4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.
TSH T3 T4 FT4 Conditions
High Low Low Low Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement
High N N N
Therapy.
N/Low Low Low Low Secondary and Tertiary Hypothyroidism
Low High High High Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low N N N Subclinical Hyperthyroidism
Low Low Low Low Central Hypothyroidism, Treatment with Hyperthyroidism
Low N High High Thyroiditis, Interfering Antibodies
N/Low High N N T3 Thyrotoxicosis, Non thyroidal causes
High High High High Pituitary Adenoma; TSHoma/Thyrotropinoma
Page 6 of 15
SIN No:IM06702866
ANTI MULLERIAN HORMONE , SERUM 5.99 ng/mL 1.03-11.10 CLIA
Comment:
Antimullerian hormone (AMH), also known as mullerian-inhibiting substance is produced by Sertoli cells of the testis in males and by
ovarian granulosa cells in females.
In males, AMH serum concentrations are elevated under 2 years and then progressively decrease until puberty, when there is a sharp
decline.
In females, AMH is produced by the granulosa cells of small growing follicles from the 36th week of gestation onwards until menopause
when levels become undetectable.
Day to day variability of AMH concentration is low, hence AMH can be measured at any day during the menstrual cycle. However, it is
best to be measured on day 2-3.
AMH values are indicative of fertility potential.
Ovarian Fertility Potential AMH(ng/ml)

Optimal fertility 4.0 – 6.8
Satisfactory fertility 2.2 – 4.0
Low fertility 0.3 – 2.2
Very low/undetectable 0.0 – 0.3
High level 6.8or more
*The above interpretation is based on certain studies, and should be looked at in conjunction with the clinical details, antral follicle counts and other investigation findings.
The serum levels of AMH positively correlate with the basal antral follicle count that is measured by transvaginal USG. However, many
times discordance is seen between the AMH values and the AFC, as AMH represents pre-antral and small follicles, and AFC is based on
the follicles visualised during USG.
AMH values considered “normal” would also vary from age to age. Occasionally, both the normal women and those with diminished
reserve have overlapping low to undetectable AMH values.
Indications for monitoring AMH are:
Ovarian hyper stimulation syndrome- It is suggested in various studies that an AMH level >3.36 ng/mL was able to predict the development
of OHSS (sensitivity=90.5% and specificity=81.3%).
To diagnose and monitor women with PCOS.
It serves as a sensitive and specific marker for early detection of recurrence in patients with ovarian granulosa cell tumours.
In males, it is used to distinguish undescended testis, in which normal male AMH concentrations are seen, from anorchia, which have
extremely low or undetectable concentrations AMH levels.
To identify testicular dysgenesis, in which low concentrations of both AMH and testosterone are seen.
In conjunction with FSH, LH and testosterone AMH is studied to diagnose precocious and delayed puberty.
Page 7 of 15
Page 8 of 15
SIN No:IM06702866
FOLLICLE STIMULATING HORMONE 6.45 mlU/mL CLIA

(FSH) , SERUM
Comment:
REFERENCE GROUP REFERENCE RANGE IN mIU/mL
FEMALES
* FOLLICULAR PHASE 2.5 – 10.2
* MID CYCLE PEAK 3.4 – 33.4
* LUTEAL PHASE 1.5 – 9.1
* PREGNANCY < 0.3
* POST MENOPAUSAL 23-116
MALES 1.4- 18.1
Abnormal FSH levels are interpreted with increased or decreased levels of other fertility hormones such as LH, estrogens,
progesterone, and testosterone.
Increased FSH levels are associated with menopause and primary ovarian hypofunction in females and primary hypogonadism in
males.Decreased FSH levels are associated with primary ovarian hyperfunction in females and primary hypergonadism in males.
Normal or decreased FSH levels are associated with polycystic ovary disease in females.
LH:LUTEINIZING HORMONE , SERUM 20.36 mlU/mL CLIA
Comment:
REFERENCE GROUP REFERENCE RANGE IN mIU/mL
FEMALES
FOLLICULAR PHASE 2.1 – 11.0
MID CYCLE PEAK 19.2 – 103
LUTEAL PHASE 1.2 – 12.8
PREGNANCY < 1.5
POST MENOPAUSAL 10.8 – 58.6
MALES 1.2 – 8.6
Page 9 of 15
Abnormal LH levels are interpreted with increased or decreased levels of other fertility hormones such as FSH, estrogens,
progesterone, and testosterone.
Increased LH levels are associated primary ovarian hypogonadism and gonadotropin secreting pituitary tumors. Decreased LH
levels are associated with Hypothalamic GnRH deficiency, Pituitary LH deficiency, Ectopic steroid hormone production, GnRH
analog treatment.
PROLACTIN , SERUM 19.53 ng/mL CLIA
Comment:
REFERENCE GROUP REFERENCE RANGE IN ng/ml
ADULT FEMALES
PRE-MENOPAUSAL 3.3 – 26.7
PREGNANCY 9.7 – 208.5
POST MENOPAUSAL 2.7 – 19.6
MALES 2.6 – 13.1
Normal prolactin secretion varies with time, which results in serum prolactin levels two to three times higher at night than during the
day.
Serum prolactin levels during the menstrual cycle are variable and commonly exhibit slight elevations during the mid-cycle.
Prolactin levels in normal individuals tend to rise in response to physiologic stimuli including sleep, exercise, nipple stimulation,
sexual intercourse, hypoglycemia, pregnancy, and surgical stress.
Prolactin values that exceed the reference values may be due to macroprolactin (prolactin bound to immunoglobulin).
Macroprolactin should be evaluated if signs and symptoms of hyperprolactinemia are absent or pituitary imaging studies are not
informative.
Increased levels of prolactin upto 100ng/mL are documented with the use of following drugs: Neuroleptics, antidepressants,
antipsychotics, medications for nausea such as metoclopramide, birth control pills, estrogen analogs, dopamine antagonists, some
blood pressure medications like methyldopa, reserpine, and opiates.
Page 10 of 15
SIN No:IM06702866
DEHYDROEPIANDROSTERONE 86.5 µg/dL 25.9-460.2 CLIA

SULPHATE - (DHEAS) , SERUM
Comment:
DHEAS is an Indicator of adrenal cortical function, especially for differential diagnosis of virilization, and investigations of hirsutism
and alopecia in women. It is also of value in the assessment of adrenarche and delayed puberty.
Levels are increased in CAH, adrenal carcinoma, Cushing syndrome caused by adrenal hyperplasia, and PCOS. Extremely high
levels (>700 or 800 μg/dL) in women are suggestive of a hormone-secreting adrenal tumor. By contrast, levels are typically
normal in the presence of ovarian tumors.
Drugs that may increase DHEA-S levels include metformin, troglitazone, prolactin, danazol, calcium channel blockers (e.g.,
diltiazem, amlodipine), and nicotine
Page 11 of 15
SIN No:IM06703629
ESTRADIOL (E2) , SERUM 89.83 pg/mL CLIA
Comment:
REFERENCE GROUP REFERENCE RANGE IN pg/mL
III. FEMALES
a. FOLLICULAR PHASE 24-114
b. MID CYCLE 62-534
c. LUTEAL PHASE 80-273
d. POST MENOPAUSAL* 20-88
IV. MALES 20-75
* NOT ON HORMONE THERAPY
E2, together with gonadotropins, is used in evaluating menstrual and fertility problems in women; in the evaluation of gynecomastia
or feminization states due to estrogen-producing tumors, menstrual cycle irregularities, and sexual maturity in female patients and in
monitoring of human menopausal gonadotropin therapy.
Oral contraceptives inhibit physiologic increase. Estradiol values from pregnant females may be affected by high levels of estriol
such as those present in the second and third trimesters of pregnancy.
Page 12 of 15
SIN No:IM06702866
TESTOSTERONE, TOTAL , SERUM 89.7 ng/dL 11-59 CLIA
Comment:
Testosterone exhibits significant circadian variations in young men, and early morning samples are recommended.
Increased levels are seen in precocious puberty (males), androgen resistance, CAH, ovarian stromal hyperthecosis.
Decreased levels are seen in delayed puberty (males), gonadotropin deficiency, testicular feminization, estrogen therapy and
certain systemic diseases
Page 13 of 15
SIN No:IM06702866
17-ALPHA-HYDROXYPROGESTERONE 1.01 ng/mL CLIA

(17-OHP) , SERUM
Comment:
New born Girls Boys
1 month 2.4-16.8 ng/mL 0.0-8.0 ng/mL
2 months 1.6-9.7 ng/mL 3.6-13.7 ng/mL
3 months 0.1-3.1 ng/mL 1.7-4.0 ng/mL
Children 3-14 years old 0.1-1.7 ng/mL
follicular phase 0.1-0.8 ng/mL

luteal phase 0.6-2.3 ng/mL
Adult female ovulatory period 0.3-1.4 ng/mL
Post ACTH <3.2 ng/mL
late pregnancy 2.0-12 ng/mL
menopause 0.13-0.51 ng/mL
Normal male 0.5-2.1ng/mL
The analysis of 17-α-OHP is 1 of the 3 analytes along with cortisol and androstenedione, that constitutes the best screening test for
congenital adrenal hyperplasia (CAH), caused by either 11- or 21-hydroxylase deficiency.
Measurement of 17-α-OHP concentrations is also utilized in evaluation of both men and women with acne vulgaris, male pattern
baldness and in some subtle forms of infertility. More recently, 17-α-OHP concentrations have been utilized in the evaluation of
androgenized women where late onset 21-hydroxylase deficiency is suspected.
In adult non-pregnant women in the childbearing age group, 17-α-OHP concentrations vary over the menstrual cycle with luteal
phase concentrations being higher than follicular phase concentrations. There is also a diurnal variation of 17-α-OHP
concentrations.
*** End Of Report ***
Page 14 of 15
Page 15 of 15
SIN No:IM06703629

LabTest 29dec2023

Uploaded by

Copyright:

Available Formats

LabTest 29dec2023

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

LabTest 29dec2023

Uploaded by

Copyright:

Available Formats

Patient Name : Ms.

PRIYANKA KUMARI Collected : 28/Dec/2023 08:18AM

HAEMOGLOBIN , WHOLE BLOOD EDTA 14.3 g/dL 12-15 Spectrophotometer

GLUCOSE, POST PRANDIAL (PP), 2 93 mg/dL 70-140 GOD - POD

LIPID PROFILE , SERUM

URIC ACID , SERUM 4.78 mg/dL 2.5-6.2 Uricase

HOMA IR (INSULIN RESISTANCE INDEX)

<3 Normal Insulin Resistance

THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM

ANTI MULLERIAN HORMONE , SERUM 5.99 ng/mL 1.03-11.10 CLIA

Ovarian Fertility Potential AMH(ng/ml)

Indications for monitoring AMH are:

FOLLICLE STIMULATING HORMONE 6.45 mlU/mL CLIA

LH:LUTEINIZING HORMONE , SERUM 20.36 mlU/mL CLIA

PROLACTIN , SERUM 19.53 ng/mL CLIA

DEHYDROEPIANDROSTERONE 86.5 µg/dL 25.9-460.2 CLIA

ESTRADIOL (E2) , SERUM 89.83 pg/mL CLIA

* NOT ON HORMONE THERAPY

TESTOSTERONE, TOTAL , SERUM 89.7 ng/dL 11-59 CLIA

17-ALPHA-HYDROXYPROGESTERONE 1.01 ng/mL CLIA

Children 3-14 years old 0.1-1.7 ng/mL

follicular phase 0.1-0.8 ng/mL

Normal male 0.5-2.1ng/mL

*** End Of Report ***

You might also like

* End Of Report *